TrialCompass TCL
Back to results
Phase 1Not yet recruitingPriority 4 · Lower priorityNCT06385522

A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System

ClinicalTrials.gov

Plain-language summary

This Phase 1 trial is testing BITR2101 for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

BITR2101 (BIOLOGICAL): TNFR2 monoclonal antibody

Drugs / treatments
BITR2101
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System

NCT06385522

Phase: Phase 1 | Status: Not yet recruiting | Priority: Lower

Plain-language summary

This Phase 1 trial is testing BITR2101 for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

What's being tested

BITR2101 (BIOLOGICAL): TNFR2 monoclonal antibody

Drugs / treatments: BITR2101

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 37 patients

Primary endpoint: to assess the safety and tolerability of BITR2101 administered intravenously every 3 weeks in order to determine the MTD, if any, and to inform the RDE

Ages: 18 Years to —

Start date: 2025-08 | Est. completion: 2027-02

Locations

0 US sites · 0 total

Contact

—

Sponsor: Boston Immune Technologies and Therapeutics (INDUSTRY)

Tags

CTCL · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06385522

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.